Search Results - "Basu, Cynthia" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors

A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors

by Harding, James J, Garrido-Laguna, Ignacio, Chen, Xiaoying, Basu, Cynthia, Dowlati, Afshin, Forgie, Alison, Hooper, Andrea T, Kamperschroer, Cris, Max, Steven I, Moreau, Allison, Shannon, Megan, Wong, Gilbert Y, Hong, David S
Published in Frontiers in immunology (14.04.2022)

Get full text

Journal Article

$Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial$

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial

by Bahlis, Nizar J., Costello, Caitlin L., Raje, Noopur S., Levy, Moshe Y., Dholaria, Bhagirathbhai, Solh, Melhem, Tomasson, Michael H., Damore, Michael A., Jiang, Sibo, Basu, Cynthia, Skoura, Athanasia, Chan, Edward M., Trudel, Suzanne, Jakubowiak, Andrzej, Gasparetto, Cristina, Chu, Michael P., Dalovisio, Andrew, Sebag, Michael, Lesokhin, Alexander M.
Published in Nature medicine (01.10.2023)

Get full text

Journal Article

First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy

First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy

by Yap, Timothy A., Giordano, Antonio, Hamilton, Erika P., LoRusso, Patricia, Bowers, Michelle, Basu, Cynthia, Billotte, Stephane, Delioukina, Maria, Liu, Feng, Yang, Jing, Sharma, Manish
Published in Journal of clinical oncology (01.06.2023)

Get full text

Journal Article

Rethinking about the dose limiting toxicities (DLTs): They can be equivocal

Rethinking about the dose limiting toxicities (DLTs): They can be equivocal

by Zhong, Wei, Bugarini, Roberto, Wang, Ling, Basu, Cynthia, Beaupre, Darrin M.
Published in Journal of clinical oncology (20.05.2019)

Get full text

Journal Article

Abstract P5-16-06: A first-in-human phase 1/2a dose escalation/expansion study of the first-in-class CDK2/4/6 inhibitor PF-06873600 alone or with endocrine therapy in patients with breast or ovarian cancer

Abstract P5-16-06: A first-in-human phase 1/2a dose escalation/expansion study of the first-in-class CDK2/4/6 inhibitor PF-06873600 alone or with endocrine therapy in patients with breast or ovarian cancer

by Yap, Timothy A., Basu, Cynthia, Goldman, Jonathan W., Gordon, Michael, Hamilton, Erika, Kelly, Adrianne, Liu, Feng, Moreau, Allison R., Neumann, Heather, Papadopoulos, Kyriakos, Rugo, Hope S., Shapiro, Geoffrey I., Vinayak, Shaveta, Zhou, Li, Jhaveri, Komal
Published in Cancer research (Chicago, Ill.) (15.02.2022)

Get full text

Journal Article

$Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1$

Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1

by Tomasson, Michael H., Bahlis, Nizar J., Costello, Caitlin, Raje, Noopur S., Levy, Moshe Y., Dholaria, Bhagirathbhai R., Solh, Melhem M., Damore, Michael A., Jiang, Sibo, Xie, Tao, Basu, Cynthia, Skoura, Athanasia, Chan, Edward Michael, Trudel, Suzanne, Jakubowiak, Andrzej J., Gasparetto, Cristina, Chu, Michael, Dalovisio, Andrew Peter, Sebag, Michael, Lesokhin, Alexander M.
Published in Journal of clinical oncology (01.06.2023)

Get full text

Journal Article

Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation

Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation

by Gamalo‐Siebers, Margaret, Savic, Jasmina, Basu, Cynthia, Zhao, Xin, Gopalakrishnan, Mathangi, Gao, Aijun, Song, Guochen, Baygani, Simin, Thompson, Laura, Xia, H. Amy, Price, Karen, Tiwari, Ram, Carlin, Bradley P.
Published in Pharmaceutical statistics : the journal of the pharmaceutical industry (01.07.2017)

Get full text

Journal Article

$Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma$

Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

by Raje, Noopur, Bahlis, Nizar Jacques, Costello, Caitlin, Dholaria, Bhagirathbhai, Solh, Melhem, Levy, Moshe Yair, Tomasson, Michael H, Damore, Michael A., Jiang, Sibo, Basu, Cynthia, Skoura, Athanasia, Chan, Edward M, Trudel, Suzanne, Jakubowiak, Andrzej, Chu, Michael P, Gasparetto, Cristina J., Dalovisio, Andrew P., Sebag, Michael, Lesokhin, Alexander M
Published in Blood (15.11.2022)

Get full text

Journal Article

$Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1$

Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1

by Jakubowiak, Andrzej J., Bahlis, Nizar J., Raje, Noopur S., Costello, Caitlin, Dholaria, Bhagirathbhai R., Solh, Melhem M., Levy, Moshe Y., Tomasson, Michael H, Dube, Harman, Damore, Michael A., Jiang, Sibo, Basu, Cynthia, Skoura, Athanasia, Chan, Edward Michael, Trudel, Suzanne, Chu, Michael P, Gasparetto, Cristina J., Dalovisio, Andrew Peter, Sebag, Michael, Lesokhin, Alexander M.
Published in Journal of clinical oncology (01.06.2022)

Get full text

Journal Article

$Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1$

Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1

by Sebag, Michael, Raje, Noopur S., Bahlis, Nizar J., Costello, Caitlin, Dholaria, Bhagirathbhai, Solh, Melhem, Levy, Moshe Y., Tomasson, Michael H., Dube, Harman, Damore, Michael A., Lon, Hoi Ken, Basu, Cynthia, Skoura, Athanasia, Chan, Edward, Trudel, Suzanne, Jakubowiak, Andrzej, Chu, Michael P., Gasparetto, Cristina, Dalovisio, Andrew P., Lesokhin, Alexander
Published in Blood (23.11.2021)

Get full text

Journal Article

$Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM)$

Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM)

by Bahlis, Nizar J., Raje, Noopur S., Costello, Caitlin, Dholaria, Bhagirathbhai R., Solh, Melhem M., Levy, Moshe Y., Tomasson, Michael H, Dube, Harman, Liu, Feng, Liao, Kai Hsin, Basu, Cynthia, Skoura, Athanasia, Chan, Edward Michael, Trudel, Suzanne, Jakubowiak, Andrzej J., Chu, Michael P, Gasparetto, Cristina, Dalovisio, Andrew, Sebag, Michael, Lesokhin, Alexander M.
Published in Journal of clinical oncology (20.05.2021)

Get full text

Journal Article

$Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)$

Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

by Raje, Noopur S., Jakubowiak, Andrzej, Gasparetto, Cristina, Cornell, Robert F., Krupka, Heike I., Navarro, Daniel, Forgie, Alison J., Udata, Chandrasekhar, Basu, Cynthia, Chou, Jeffrey, Leung, Abraham, Lesokhin, Alexander M.
Published in Blood (13.11.2019)

Get full text

Journal Article

$Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)$

Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

by Lesokhin, Alexander M., Levy, Moshe Y., Dalovisio, Andrew P., Bahlis, Nizar J., Solh, Melhem, Sebag, Michael, Jakubowiak, Andrzej, Jethava, Yogesh S., Costello, Caitlin L., Chu, Michael P., Savona, Michael R., Gasparetto, Cristina, Trudel, Suzanne, Chou, Jeffrey, Udata, Chandrasekhar, Basu, Cynthia, Krupka, Heike I., Raje, Noopur S.
Published in Blood (05.11.2020)

Get full text

Journal Article

$OAB-026: MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM)$

OAB-026: MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM)

by Dholaria, Bhagirathbhai, Bahlis, Nizar, Raje, Noopur, Costello, Caitlin, Solh, Melhem, Levy, Moshe, Tomasson, Michael, Dube, Harman, Damore, Michael, Lon, Hoi Kei, Basu, Cynthia, Skoura, Athanasia, Chan, Edward, Trudel, Suzanne, Jakubowiak, Andrzej, Chu, Michael, Gasparetto, Cristina, Dalovisio, Andrew, Sebag, Michael, Lesokhin, Alexander
Published in Clinical lymphoma, myeloma and leukemia (01.10.2021)

Get full text

Journal Article

$MM-379: MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM)$

MM-379: MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM)

by Levy, Moshe, Bahlis, Nizar, Raje, Noopur, Costello, Caitlin, Dholaria, Bhagirathbhai, Solh, Melhem, Tomasson, Michael, Dube, Harman, Damore, Michael, Lon, Hoi Kei, Basu, Cynthia, Skoura, Athanasia, Chan, Edward, Trudel, Suzanne, Jakubowiak, Andrzej, Chu, Michael, Gasparetto, Cristina, Dalovisio, Andrew, Sebag, Michael, Lesokhin, Alexander
Published in Clinical lymphoma, myeloma and leukemia (01.09.2021)

Get full text

Journal Article

$Poster: MM-379: MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM)$

Poster: MM-379: MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM)

by Levy, Moshe, Bahlis, Nizar, Raje, Noopur, Costello, Caitlin, Dholaria, Bhagirathbhai, Solh, Melhem, Tomasson, Michael, Dube, Harman, Damore, Michael, Lon, Hoi Kei, Basu, Cynthia, Skoura, Athanasia, Chan, Edward, Trudel, Suzanne, Jakubowiak, Andrzej, Chu, Michael, Gasparetto, Cristina, Dalovisio, Andrew, Sebag, Michael, Lesokhin, Alexander
Published in Clinical lymphoma, myeloma and leukemia (01.09.2021)

Get full text

Journal Article

Pharmacokinetic/pharmacodynamic data extrapolation models for improved pediatric efficacy and toxicity estimation, with application to secondary hyperparathyroidism

Pharmacokinetic/pharmacodynamic data extrapolation models for improved pediatric efficacy and toxicity estimation, with application to secondary hyperparathyroidism

by Basu, Cynthia, Ma, Xiaoye, Mo, May, Xia, Hong Amy, Brundage, Richard, Al‐Kofahi, Mahmoud, Carlin, Bradley P.
Published in Pharmaceutical statistics : the journal of the pharmaceutical industry (01.11.2020)

Get full text

Journal Article

A model‐based approach to assess the exposure–response relationship of Lorenzo's oil in adrenoleukodystrophy

A model‐based approach to assess the exposure–response relationship of Lorenzo's oil in adrenoleukodystrophy

by Ahmed, Mariam A., Kartha, Reena V., Brundage, Richard C., Cloyd, James, Basu, Cynthia, Carlin, Bradley P., Jones, Richard O., Moser, Ann B., Fatemi, Ali, Raymond, Gerald V.
Published in British journal of clinical pharmacology (01.06.2016)

Get full text

Journal Article

Fragility Index for Time-to-Event Endpoints in Single-Arm Clinical Trials

Fragility Index for Time-to-Event Endpoints in Single-Arm Clinical Trials

by Maity, Arnab Kumar, Garg, Jhanvi, Basu, Cynthia
Year of Publication 25.11.2024

Get full text

Journal Article

A hierarchical Bayesian approach for combining pharmacokinetic/pharmacodynamic modeling and Phase IIa trial design in orphan drugs: Treating adrenoleukodystrophy with Lorenzo's oil

A hierarchical Bayesian approach for combining pharmacokinetic/pharmacodynamic modeling and Phase IIa trial design in orphan drugs: Treating adrenoleukodystrophy with Lorenzo's oil

by Basu, Cynthia, Ahmed, Mariam A., Kartha, Reena V., Brundage, Richard C., Raymond, Gerald V., Cloyd, James C., Carlin, Bradley P.
Published in Journal of biopharmaceutical statistics (01.11.2016)

Get full text

Journal Article